4D Molecular Therapeutics enrolls first patients in Phase 3 4SIGHT trial of 4D-150 for diabetic macular edema

• 4D Molecular Therapeutics enrolled the first patients in 4SIGHT, a global Phase 3 trial of 4D-150 in treatment-naïve diabetic macular edema.
• Updated two-year SPECTRA results were presented, supporting durable vision and anatomical improvements with reduced need for frequent injections.
• The program advances 4D-150 into a second large retinal market, extending its late-stage pipeline beyond wet AMD.
• Regulators have discussed a potential filing strategy that relies on this single DME Phase 3 study alongside prior DME and wet AMD data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED9834464) on September 28, 2026, and is solely responsible for the information contained therein.